Review of regimens for the treatment of DLBCL and high-grade B-celllymphoma
| Study . | Design . | Sample size by treatment . | Outcome . |
|---|---|---|---|
| Petrich et al3 | Retrospective, multicenter | R-CHOP (n = 100) | Median PFS: |
| R-HyperCVAD (n = 65) | R-CHOP: 7.8 mo | ||
| DA EPOCH-R (n = 64) | Intensive regimens including R-HyperCVAD, DA EPOCH-R, and CODOX-M/IVAC: 21.6 mo; P = .0463 | ||
| R-CODOX-M/IVAC (n = 42) | Median OS: | ||
| Other (n = 40) | No difference between regimens | ||
| Oki et al4 | Retrospective, single center | R-CHOP (n = 57) | CR: |
| R-HyperCVAD/MA (n = 34) | R-CHOP 40%; R-EPOCH 68%; R-HyperCVAD/MA 68% | ||
| DA EPOCH-R (n = 28) | EFS: | ||
| R-CODOX-M (n = 2) | R-EPOCH vs R-CHOP HR of 0.37 (0.18-0.77; P = ..008) | ||
| Other (n = 8) | R-HyperCVAD/MA vs R-CHOP HR 0.61 (0.36-1.05; P = .074) | ||
| OS: | |||
| R-EPOCH vs R-CHOP HR of 0.47 (0.19-1.14; P = .96) | |||
| R-HyperCVAD/MA vs R-CHOP HR of 0.67 (0.37-1.21; P = .187) | |||
| Howlett et al6 | Meta-analysis | R-CHOP (n = 180) | Median PFS: |
| DA EPOCH-R (n = 91) | R-CHOP 12.1 mo | ||
| Dose-intensive treatment including R-HyperCVAD/MA and R-CODOX-M/IVAC (n = 123) | DA EPOCH-R 22.2 mo | ||
| Dose intensive 18.9 mo | |||
| Relative risk reduction for progression of 34% for DA EPOCH-R compared with R-CHOP (P = .032) | |||
| Insignificant relative risk reduction of 26% for dose intensive treatments vs R-CHOP (P = .088) |
| Study . | Design . | Sample size by treatment . | Outcome . |
|---|---|---|---|
| Petrich et al3 | Retrospective, multicenter | R-CHOP (n = 100) | Median PFS: |
| R-HyperCVAD (n = 65) | R-CHOP: 7.8 mo | ||
| DA EPOCH-R (n = 64) | Intensive regimens including R-HyperCVAD, DA EPOCH-R, and CODOX-M/IVAC: 21.6 mo; P = .0463 | ||
| R-CODOX-M/IVAC (n = 42) | Median OS: | ||
| Other (n = 40) | No difference between regimens | ||
| Oki et al4 | Retrospective, single center | R-CHOP (n = 57) | CR: |
| R-HyperCVAD/MA (n = 34) | R-CHOP 40%; R-EPOCH 68%; R-HyperCVAD/MA 68% | ||
| DA EPOCH-R (n = 28) | EFS: | ||
| R-CODOX-M (n = 2) | R-EPOCH vs R-CHOP HR of 0.37 (0.18-0.77; P = ..008) | ||
| Other (n = 8) | R-HyperCVAD/MA vs R-CHOP HR 0.61 (0.36-1.05; P = .074) | ||
| OS: | |||
| R-EPOCH vs R-CHOP HR of 0.47 (0.19-1.14; P = .96) | |||
| R-HyperCVAD/MA vs R-CHOP HR of 0.67 (0.37-1.21; P = .187) | |||
| Howlett et al6 | Meta-analysis | R-CHOP (n = 180) | Median PFS: |
| DA EPOCH-R (n = 91) | R-CHOP 12.1 mo | ||
| Dose-intensive treatment including R-HyperCVAD/MA and R-CODOX-M/IVAC (n = 123) | DA EPOCH-R 22.2 mo | ||
| Dose intensive 18.9 mo | |||
| Relative risk reduction for progression of 34% for DA EPOCH-R compared with R-CHOP (P = .032) | |||
| Insignificant relative risk reduction of 26% for dose intensive treatments vs R-CHOP (P = .088) |
CODOX-M/IVAC, cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, and etoposide cytarabine; EFS, event free-survival.